Imunon, Inc. IMNN
0.57 USD -0.02 (-2.59%)
Regular-session close
0.57 0.00 0.00%
After hours · Nov 19, 4:45 PM ET
0.54 Day range 0.6051
0.50 52-week range 4.35
- YTD
- -85.17%
- 1 year
- -85.05%
News
seekingalpha.com Imunon, Inc. (IMNN) Q3 2026 Earnings Call Transcript Imunon, Inc. (IMNN) Q3 2026 Earnings Call Transcript
benzinga.com Imunon Q3 2026 Earnings Call Transcript Imunon (NASDAQ:IMNN) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Imunon Q3 EPS $(0.64) Misses $(0.55) Estimate Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.55) by 16.36 percent. This is a 44.83 percent increase over losses of $(1.16)…
globenewswire.com IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer
globenewswire.com IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Curis (NASDAQ:CRIS) stock moved upwards by 83.5% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $1.7 million. SCWorx (NASDAQ:WORX) stock increased by…
globenewswire.com IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026 LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…benzinga.com IMUNON Sells ThermoDox Rights To VoxelDox; IMUNON Receive Equity Ownership Stake In VoxelDox With Payments Of Up To $16.5M Contingent On Meeting Development Milestones And Royalties Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma TrialSale Reinforces IMUNON's…
globenewswire.com IMUNON Announces Strategic Sale of ThermoDox® Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial
globenewswire.com IMUNON to Participate in Upcoming Investor Conferences LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy…
globenewswire.com IMUNON Converts $1.2 Million of Debt-to-Equity Unique investment vehicle provides efficient access to equity capitalOutstanding debt of the original Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE,…
globenewswire.com IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan 2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory…
seekingalpha.com Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript
globenewswire.com IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date
globenewswire.com IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens
globenewswire.com IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J.
globenewswire.com IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones
seekingalpha.com Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript
globenewswire.com IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION 2…
globenewswire.com IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism
globenewswire.com IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial Lower rate of minimal residual disease (MRD)Higher ctDNA…
benzinga.com Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 minimal residual disease (MRD) translational trial.
globenewswire.com IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer…
